SCHEMBL2275595

SCHEMBL2275595

Nc1nc2ccc(C=O)cc2s1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.56
MAPT P10636 2/20 0.56
HTT P42858 2/20 0.56
AXL P30530 1/20 0.56
GFER P55789 1/20 0.56
GAA P10253 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
ALDH1A1 P00352 3/20 0.56
HSD17B10 Q99714 2/20 0.56
KDM4E B2RXH2 1/20 0.56
LMNA P02545 1/20 0.56
PKM P14618 1/20 0.56
HPGD P15428 1/20 0.56
KMT2A Q03164 1/20 0.56
CYP3A4 P08684 3/20 0.53
TSHR P16473 2/20 0.53
TDP1 Q9NUW8 1/20 0.53
NPC1 O15118 3/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
PI4KA P42356 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27522839 0.84 RAB9A (0.62) RAB9AMAPTHTTAXLGFER
SCHEMBL12373172 0.80 CYP2A6 (0.42) RAB9AMAPTHTTALDH1A1HSD17B10
SCHEMBL4533808 0.79 SMN1; SMN2 (0.56) RAB9AMAPTHTTGAAL3MBTL1
SCHEMBL10951998 0.79 CYP2A6 (0.41) RAB9AMAPTAXLGFERALDH1A1
SCHEMBL8170041 0.79 KMT2A (0.47) RAB9AMAPTHTTGAAALDH1A1
SCHEMBL12345077 0.78 MAPT (0.69) RAB9AMAPTGFERGAAALDH1A1
SCHEMBL13539413 0.77 RAB9A (0.68) RAB9AMAPTHTTAXLGFER
SCHEMBL12566875 0.76 INSR (0.42) RAB9AMAPTL3MBTL1ALDH1A1KDM4E
SCHEMBL5164106 0.76 RAB9A (0.66) RAB9AMAPTHTTAXLGFER
SCHEMBL5440540 0.76 RAB9A (0.49) RAB9AMAPTHTTAXLGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1236712-B1 AMIDINOPHENYLPYRUVIC ACID DERIVATIVE AJINOMOTO KK (JP) 2008-08-06 EP claimed
US-6710056-B2 PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVE AN EXCELLENT ANTAGONISTIC EFFECT AGAINST ACTIVATED BLOOD COAGULATION FACTOR VII. AJINOMOTO CO., INC. (JP) 2004-03-23 US claimed
US-20030109547-A1 Amidinophenylpyruvic acid derivatives AJINOMOTO CO. INC (JP) 2003-06-12 US claimed
EP-1236712-A1 AMIDINOPHENYLPYRUVIC ACID DERIVATIVE Ajinomoto Co., Inc. (JP) 2002-09-04 EP claimed
EP-4583870-A2 MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER Mito Biopharma, LLC (US) 2025-07-16 EP disclosed
WO-2024054766-A2 MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER MITO BIOPHARMA, LLC (US) 2024-03-14 WO disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-20170015645-A1 SUBSTITUTED PYRAN DERIVATIVES UNIV WAYNE STATE (US) 2017-01-19 US disclosed
US-20170015645-A1 SUBSTITUTED PYRAN DERIVATIVES UNIV WAYNE STATE (US) 2017-01-19 US disclosed
US-9458124-B2 Substituted pyran derivatives WAYNE STATE UNIVERSITY (US) 2016-10-04 US disclosed
US-9458124-B2 Substituted pyran derivatives WAYNE STATE UNIVERSITY (US) 2016-10-04 US disclosed
EP-2266981-B1 Benzothiazole compounds useful as kinase inhibitors BRISTOL MYERS SQUIBB CO (US) 2016-07-06 EP disclosed
US-20030109547-A1 Amidinophenylpyruvic acid derivatives AJINOMOTO CO. INC (JP) 2003-06-12 US disclosed
EP-1236712-A1 AMIDINOPHENYLPYRUVIC ACID DERIVATIVE Ajinomoto Co., Inc. (JP) 2002-09-04 EP disclosed
EP-0195947-B1 Beta-lactam antibiotics, process for their preparation and their use as and in medicaments BAYER AG (DE) 1996-04-24 EP disclosed
CN-1017335-B PROCESS FOR PREPARING BETA-LACTAM ANTIBIOTICS BAYER AG (DE) 1992-07-08 CN disclosed
US-RE33948-E Bactericides, animal growth regulators BAYER AKTIENGESELLSCHAFT (DE) 1992-06-02 US disclosed
US-4748163-A Novel β-lactam antibiotics BAYER AKTIENGESELLSCHAFT (DE) 1988-05-31 US disclosed
EP-0195947-A2 Beta-lactam antibiotics, process for their preparation and their use as and in medicaments BAYER AG (DE) 1986-10-01 EP disclosed
CN-86101382-A Prepare the method for β-Nei Xiananleikangshengsu and the application in medicine thereof 1986-09-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170015645-A1 SUBSTITUTED PYRAN DERIVATIVES SLC18A2, SLC6A4, SLC6A3 RAB9A 1166/4885MAPT 386/4885HTT 296/4885
US-20030109547-A1 Amidinophenylpyruvic acid derivatives HABP2, F2, F7 RAB9A 1858/4885MAPT 4059/4885HTT 4129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.